NCI sponsors the ANCHOR Study through the AIDS Malignancy Consortium
The Anal Cancer HSIL (High-Grade Squamous Intraepithelial Lesion) Outcomes Research (ANCHOR) Study is a multi-center Phase III clinical trial to determine if treating anal HSIL is effective in reducing the incidence of anal cancer in HIV-infected individuals. The trial is now open for enrollment. Approximately 17,385 men and women age 35 and older will be screened to identify 5,058 eligible participants with previously untreated HSIL. Patients will be randomly assigned to treatment or active monitoring arms, and followed every six months for HSIL outcomes for up to five years.